Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction

Figure 1. Mean percent change (%) from baseline to 3-month follow-up; red—OMT+SGLT2i group, blue—OMT control group; (A)—mean percent change in right ventricular free wall strain between groups from baseline to 3mFU; (B)—mean percent change in TR maximal pressure gradient between groups from baseline to 3mFU; (C)—mean percent change in maximal TR velocity between groups from baseline to 3mFU; (D)—mean percent change in TAPSE/SPAP ratio between groups from baseline to 3mFU. * Two-tailed significance values (p) were reported in all instances, while the results that reached p < 0.05 were considered to be statistically significant.

Figure 2. Mean percent change (%) from baseline to 3-month follow-up; red—OMT+SGLT2i group, blue—OMT control group; (A)—mean percent change in tricuspid annular plane systolic excursion (TAPSE) between groups from baseline to 3mFU; (B)—mean percent change in Doppler tissue imaging-derived tricuspid lateral annular systolic velocity (s’ wave) between groups from baseline to 3mFU; (C)—mean percent change in right ventricular ejection fraction measured by three-dimensional echocardiography between groups from baseline to 3mFU; (D)—mean percent change in fractional area change (FAC) between groups from baseline to 3mFU.

Figure 3. Upper image—proportion of patients from the OMT control group with the right ventricular free wall strain value (RV FWS) of −16% or more positive to absolute zero value (red color); or above −16% and more negative value from absolute zero value. Bottom image—proportion of patients from the OMT+ SGLT2i+ group with the right ventricular free wall strain value (RV FWS) of −16% or more positive to absolute zero (red color); or over −16% and more negative value from absolute zero.